These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 16252586)

  • 1. Cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta.
    Amarasena S; Lekamwasam S; Jayawardena P
    Ceylon Med J; 2005 Sep; 50(3):137-8. PubMed ID: 16252586
    [No Abstract]   [Full Text] [Related]  

  • 2. Osteogenesis imperfecta and intravenous pamidronate.
    Banerjee I; Shortland GJ; Evans WD; Gregory JW
    Arch Dis Child; 2002 Dec; 87(6):562-3. PubMed ID: 12456578
    [No Abstract]   [Full Text] [Related]  

  • 3. Bone densitometry in pediatric patients treated with pamidronate.
    Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
    Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclic pamidronate therapy in children with osteogenesis imperfecta.
    Salehpour S; Tavakkoli S
    J Pediatr Endocrinol Metab; 2010; 23(1-2):73-80. PubMed ID: 20432809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.
    Zeitlin L; Rauch F; Plotkin H; Glorieux FH
    Pediatrics; 2003 May; 111(5 Pt 1):1030-6. PubMed ID: 12728084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.
    Andiran N; Alikasifoglu A; Gonc N; Ozon A; Kandemir N; Yordam N
    J Pediatr Endocrinol Metab; 2008 Jan; 21(1):63-72. PubMed ID: 18404974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients.
    Giraud F; Meunier PJ
    Joint Bone Spine; 2002 Oct; 69(5):486-90. PubMed ID: 12477233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta.
    Choi JH; Shin YL; Yoo HW
    J Korean Med Sci; 2007 Apr; 22(2):209-12. PubMed ID: 17449925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclic intravenous pamidronate in a very low-birthweight infant with osteogenesis imperfecta.
    Eto S; Hada S; Fukuhara R; Nishimura G; Takagi M
    Pediatr Int; 2018 May; 60(5):485-486. PubMed ID: 29700899
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of intravenous pamidronate treatment in children with osteogenesis imperfecta.
    Atta I; Iqbal F; Lone SW; Ibrahim M; Khan YN; Raza J
    J Coll Physicians Surg Pak; 2014 Sep; 24(9):653-7. PubMed ID: 25233970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
    Löwing K; Aström E; Oscarsson KA; Söderhäll S; Eliasson AC
    Acta Paediatr; 2007 Aug; 96(8):1180-3. PubMed ID: 17578486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
    Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
    Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta.
    Aström E; Söderhäll S
    Acta Paediatr; 1998 Jan; 87(1):64-8. PubMed ID: 9510450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pamidronate affects the mandibular cortex of children with osteogenesis imperfecta.
    Apolinário AC; Figueiredo PT; Guimarães AT; Acevedo AC; Castro LC; Paula AP; Paula LM; Melo NS; Leite AF
    J Dent Res; 2015 Mar; 94(3 Suppl):95S-102S. PubMed ID: 25608973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta.
    González E; Pavía C; Ros J; Villaronga M; Valls C; Escolá J
    J Pediatr Endocrinol Metab; 2001 May; 14(5):529-33. PubMed ID: 11393574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vertebral morphometry in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate treatment.
    Land C; Rauch F; Munns CF; Sahebjam S; Glorieux FH
    Bone; 2006 Oct; 39(4):901-6. PubMed ID: 16730480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monthly intravenous alendronate treatment can maintain bone strength in osteogenesis imperfecta patients following cyclical pamidronate treatment.
    Harada D; Kashiwagi H; Ueyama K; Oriyama K; Hanioka Y; Sakamoto N; Kondo K; Kishimoto K; Izui M; Nagamatsu Y; Yamada H; Tanaka H; Namba N; Seino Y
    J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1391-1397. PubMed ID: 33031051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Musculoskeletal functional outcomes in children with osteogenesis imperfecta: associations with disease severity and pamidronate therapy.
    Sousa T; Bompadre V; White KK
    J Pediatr Orthop; 2014 Jan; 34(1):118-22. PubMed ID: 23863411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta.
    Palomo T; Andrade MC; Peters BS; Reis FA; Carvalhaes JT; Glorieux FH; Rauch F; Lazaretti-Castro M
    Calcif Tissue Int; 2016 Jan; 98(1):42-8. PubMed ID: 26387692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.